Filgrastim

Near Add Your Location

Sorting 6 by

Accepting patients

Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Horse Anti-Thymocyte Globulin (hATG)

Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
  • White Blood Cell Stimulant
  • Steroid
  • Phase 2

Accepting patients

Gemtuzumab as Part of Chemotherapy

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
  • Antibody Drug Conjugate (ADC)
  • Hypomethylating Agents (HMA)
  • White Blood Cell Stimulant
  • CD33
  • Phase 2

Accepting patients

Venetoclax w/ Combination Chemotherapy

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
  • BCL-2 Inhibitor
  • Chemotherapy
  • Phase 1/2

Accepting patients

MORE

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
  • Hypomethylating Agents (HMA)
  • White Blood Cell Stimulant
  • Maintenance
  • Phase 2

Accepting patients

Decitabine Combination Therapy Pre-ASCT

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
  • Allogeneic Stem Cell Transplant
  • Chemotherapy
  • Hypomethylating Agents (HMA)
  • Phase 1/2